All In Biotech

Drug Trial Radar · NCT02994927

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine

Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 331 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

331

Actual

Start

Mar 15, 2017

Primary completion

Sep 7, 2019

Study completion Nov 1, 2019

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.

Conditions

  • ANCA-Associated Vasculitis

Interventions

  • AvacopanDrug

    Avacopan 30 mg twice daily orally for 52 weeks (364 days): \- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose. Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days): * Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule. * Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day.

  • PrednisoneDrug

    Avacopan-matching placebo twice daily orally for 52 weeks (364 days): \- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose. Oral prednisone tapering regimen over 20 weeks (140 days): * Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule. * Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day.

  • CyclophosphamideDrug

    Orally or intravenously administered

  • RituximabBiological

    Intravenously administered

  • AzathioprineDrug

    Orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Disease Remission at Week 26Time frame: Week 26
  2. Percentage of Subjects Achieving Sustained Disease Remission at Week 52Time frame: Week 52

Locations

198 sites in 20 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Huntsville, Alabama

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Santa Monica, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Daytona Beach, Florida

  • Clinical Trial Site

    Tampa, Florida

  • Clinical Trial Site

    Atlanta, Georgia

  • Clinical Trial Site

    Meridian, Idaho

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Indianapolis, Indiana

  • Clinical Trial Site

    Kansas City, Kansas

  • Clinical Trial Site

    Lexington, Kentucky

  • Clinical Trial Site

    Shreveport, Louisiana

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    Minneapolis, Minnesota

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Great Neck, New York

  • Clinical Trial Site

    Mineola, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Chapel Hill, North Carolina

  • Clinical Trial Site

    Greenville, North Carolina

  • Clinical Trial Site

    Winston-Salem, North Carolina

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Columbus, Ohio

  • Clinical Trial Site

    Duncansville, Pennsylvania

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Providence, Rhode Island

  • Clinical Trial Site

    Charleston, South Carolina

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Salt Lake City, Utah

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.